PC
CAPR icon

Pier Capital’s Capricor Therapeutics CAPR Stock Holding History

Pier Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
111,908
+67,507
+152% +$2.05M 0.36% 97
2026
Q1 		$1.35M Buy
+44,401
New +$1.18M 0.22% 97
2025
Q4 		– Sell
-496,554
Closed -$3.58M – 132
2025
Q3 		$3.58M Buy
496,554
+128,837
+35% +$949K 0.56% 88
2025
Q2 		$3.65M Buy
367,717
+13,536
+4% +$143K 0.56% 84
2025
Q1 		$3.36M Buy
+354,181
New +$4.92M 0.56% 83

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pier Capital's CAPR Position: Q2 2026 in Review

Pier Capital increased its Capricor Therapeutics (CAPR) stake by 152% in Q2 2026, buying an estimated $2.05M and bringing the position to 111,908 shares worth $2.69M. The position accounts for 0.36% of the portfolio, ranked #97.

Pier Capital first reported a position in CAPR in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.65M in Q2 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Pier Capital held 111,908 shares of Capricor Therapeutics worth $2.69M as of Q2 2026.
  • Pier Capital bought 67,507 Capricor Therapeutics shares in Q2 2026, an estimated $2.05M.
  • Capricor Therapeutics made up 0.36% of Pier Capital's portfolio in Q2 2026, its #97 holding.
  • Pier Capital first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Pier Capital's Capricor Therapeutics position peaked at $3.65M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.